Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19469566 | 0.91 | POLA1 (0.54) | POLA1SMN1; SMN2CYP3A4CYP2C9TSHR | |
| SCHEMBL19469620 | 0.91 | POLA1 (0.54) | POLA1SMN1; SMN2CYP3A4CYP2C9TSHR | |
| SCHEMBL19469524 | 0.91 | POLA1 (0.54) | POLA1SMN1; SMN2CYP3A4CYP2C9TSHR | |
| SCHEMBL7172371 | 0.87 | SMN1; SMN2 (0.56) | POLA1SIGMAR1SMN1; SMN2NPC1POLB | |
| SCHEMBL28760516 | 0.85 | POLA1 (0.46) | POLA1SIGMAR1SMN1; SMN2NPC1POLB | |
| SCHEMBL5396757 | 0.82 | POLA1 (0.52) | POLA1SIGMAR1NPC1POLBRAB9A | |
| SCHEMBL7967461 | 0.82 | POLA1 (0.52) | POLA1SIGMAR1NPC1POLBRAB9A | |
| SCHEMBL1846867 | 0.81 | POLA1 (0.51) | POLA1SIGMAR1NPC1POLBRAB9A | |
| SCHEMBL19469571 | 0.81 | SMN1; SMN2 (0.56) | POLA1SMN1; SMN2KDM1ACYP3A4CYP2C19 | |
| SCHEMBL19520534 | 0.81 | SMN1; SMN2 (0.56) | POLA1SMN1; SMN2KDM1ACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012140-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | POLA1 2368/4885SIGMAR1 1955/4885SMN1; SMN2 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.